Rankings
▼
Calendar
TGTX FY 2024 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
TGTX
TG Therapeutics, Inc.
$5B
FY 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$329M
+40.8% YoY
Gross Profit
$291M
88.3% margin
Operating Income
$42M
12.7% margin
Net Income
$23M
7.1% margin
EPS (Diluted)
$0.15
Cash Flow
Operating Cash Flow
-$41M
Free Cash Flow
-$41M
Stock-Based Comp.
$43M
Balance Sheet
Total Assets
$578M
Total Liabilities
$355M
Stockholders' Equity
$222M
Cash & Equivalents
$180M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$329M
$234M
+40.8%
Gross Profit
$291M
$220M
+32.3%
Operating Income
$42M
$21M
+103.2%
Net Income
$23M
$13M
+84.5%
← Q4 2023
All Quarters
Q1 2024 →